{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:02:18Z","timestamp":1790038938462,"version":"4.0.1"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0232395","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T17:58:06Z","timestamp":1588269486000},"page":"e0232395","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-0401","authenticated-orcid":true,"given":"Taylor-Jade","family":"Woods","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-1711","authenticated-orcid":true,"given":"Fisaha","family":"Tesfay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Speck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billingsley","family":"Kaambwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"issue":"2","key":"pone.0232395.ref001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/db16-0806","article-title":"Differentiation of diabetes by pathophysiology, natural History, and prognosis","volume":"66","author":"JS Skyler","year":"2017","journal-title":"Diabetes"},{"issue":"S1","key":"pone.0232395.ref002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/dmrr.2694","article-title":"The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: development of an evidence-based global consensus","volume":"32","author":"K Bakker","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"issue":"9498","key":"pone.0232395.ref003","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0140-6736(05)67698-2","article-title":"The global burden of diabetic foot disease","volume":"366","author":"AJM Boulton","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"pone.0232395.ref004","doi-asserted-by":"crossref","first-page":"e000795","DOI":"10.1136\/bmjdrc-2019-000795","article-title":"Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period","volume":"7","author":"C-W Lin","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"8","key":"pone.0232395.ref005","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.2337\/dc06-0306","article-title":"Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures","volume":"29","author":"WJ Jeffcoate","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"pone.0232395.ref006","doi-asserted-by":"crossref","first-page":"e0177916","DOI":"10.1371\/journal.pone.0177916","article-title":"Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers","volume":"12","author":"L Jia","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"pone.0232395.ref007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7547\/0980489","article-title":"Mortality rates and diabetic foot ulcers is it time to communicate mortality risk to patients with diabetic foot ulceration?","volume":"98","author":"JM Robbins","year":"2008","journal-title":"J Am Podiatr Med Assoc"},{"issue":"S1","key":"pone.0232395.ref008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/dmrr.2245","article-title":"Cost of treating diabetic foot ulcers in five different countries","volume":"28","author":"P Cavanagh","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"pone.0232395.ref009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.avsg.2015.11.025","article-title":"Burden of infected diabetic foot ulcers on hospital admissions and costs","volume":"33","author":"CW Hicks","year":"2016","journal-title":"Ann Vasc Surg"},{"issue":"5","key":"pone.0232395.ref010","first-page":"1","article-title":"Hyperbaric oxygen therapy for the treatment of diabetic foot ulcers: a health technology assessment","volume":"17","author":"Health Quality Ontario","year":"2017","journal-title":"Ont Health Technol Assess Ser"},{"issue":"12","key":"pone.0232395.ref011","first-page":"1","article-title":"Fibreglass total contact casting, removable cast walkers, and irremovable cast walkers to treat diabetic neuropathic foot ulcers: a health technology assessment","volume":"17","author":"Health Quality Ontario","year":"2017","journal-title":"Ont Health Technol Assess Ser"},{"key":"pone.0232395.ref012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/TCRM.S131193","article-title":"Evaluation of negative-pressure wound therapy for patients with diabetic foot ulcers: systematic review and meta-analysis","volume":"13","author":"S Liu","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"pone.0232395.ref013","doi-asserted-by":"crossref","DOI":"10.5070\/D3228032089","article-title":"Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success","volume":"22","author":"M Saco","year":"2016","journal-title":"Dermatol Online J"},{"issue":"7","key":"pone.0232395.ref014","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"pone.0232395.ref015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"D Husereau","year":"2013","journal-title":"Value Health"},{"issue":"6","key":"pone.0232395.ref016","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/art.1790100610","article-title":"Rating satisfaction research: Is it poor, fair, good, very good, or excellent?","volume":"10","author":"T di Palo Michele","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0232395.ref017","article-title":"A systematic review of economic evaluations of population-based sodium reduction interventions","volume":"12","author":"SF Hope","year":"2017","journal-title":"PLoS One"},{"key":"pone.0232395.ref018","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1472-6963-12-253","article-title":"A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments","volume":"12","author":"A Langer","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pone.0232395.ref019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.eururo.2014.11.038","article-title":"Prognostic value of the cell cycle progression score in patients with prostate cancer: A systematic review and meta-analysis","volume":"69","author":"S Sommariva","year":"2016","journal-title":"Eur Urol"},{"key":"pone.0232395.ref020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"J Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"issue":"3","key":"pone.0232395.ref021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2340\/0001555576231235","article-title":"Cavity foot ulcers in diabetic patients: A comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial","volume":"76","author":"J Apelqvist","year":"1996","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"pone.0232395.ref022","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2753.2006.00770.x","article-title":"A model to analyse costs and benefit of intensified diabetic foot care in Austria","volume":"13","author":"W Habacher","year":"2007","journal-title":"J Eval Clin Pract"},{"issue":"6","key":"pone.0232395.ref023","first-page":"412","article-title":"Pharmacoeconomic analysis of guidelines for treating mild diabetic foot infections: A decision-tree model for Canada","volume":"61","author":"I Chow","year":"2008","journal-title":"Can J Hosp Pharm"},{"issue":"3","key":"pone.0232395.ref024","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13300-016-0183-x","article-title":"Cost-effectiveness analysis of d-Nav for people with diabetes at high risk of neuropathic foot ulcers","volume":"7","author":"W Green","year":"2016","journal-title":"Diabetes Ther"},{"issue":"2","key":"pone.0232395.ref025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.22159\/ajpcr.2018.v11i2.22441","article-title":"Appropriate empirical management of microbial infections in a tertiary care hospital: A cost-effectiveness approach","volume":"11","author":"N Onchari Divinah","year":"2018","journal-title":"Asian J Pharm Clin Res"},{"issue":"12","key":"pone.0232395.ref026","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2165\/11310080-000000000-00000","article-title":"Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin\/tazobactam in the treatment of diabetic foot infections in the UK","volume":"27","author":"JP Jansen","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"pone.0232395.ref027","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.1995.03520330042035","article-title":"Foot infections in diabetic patients. Decision and cost-effectiveness analyses","volume":"273","author":"MH Eckman","year":"1995","journal-title":"JAMA"},{"issue":"14 Spec No","key":"pone.0232395.ref028","first-page":"SP607","article-title":"Clinical evidence for and cost-effectiveness of advanced cellular tissue products for the treatment of diabetic foot ulcers","volume":"24","author":"R Kirsner","year":"2018","journal-title":"Am J Manag Care"},{"issue":"1","key":"pone.0232395.ref029","first-page":"S53","article-title":"A cost-utility evaluation of best practice implementation of leg and foot ulcer care in the Ontario community","volume":"5","author":"R Shannon","year":"2007","journal-title":"Wound Care Canada"},{"issue":"12","key":"pone.0232395.ref030","first-page":"14","article-title":"Descriptive, longitudinal study results applied to statistical models to assess the impact of early microbiological cultures on the economic burden of treatment for infected diabetic foot ulcers at a mexican public health facility","volume":"62","author":"LM Balderas-Pena","year":"2016","journal-title":"Ostomy Wound Manage"},{"issue":"1","key":"pone.0232395.ref031","first-page":"10","article-title":"The problems and cost-effectiveness analysis of diabetic foot infections","volume":"16","author":"MS G\u00f6nen","year":"2012","journal-title":"Turk J Endocrinol Metab"},{"key":"pone.0232395.ref032","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/CEOR.S11981","article-title":"On the decision rules of cost-effective treatment for patients with diabetic foot syndrome","volume":"2","author":"JE Goulionis","year":"2010","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"pone.0232395.ref033","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/iwj.12816","article-title":"Diabetic foot ulcer management in clinical practice in the UK: Costs and outcomes","volume":"15","author":"JF Guest","year":"2018","journal-title":"Int Wound J"},{"issue":"34","key":"pone.0232395.ref034","doi-asserted-by":"crossref","DOI":"10.3310\/hta21340","article-title":"Evaluation of the effectiveness and cost-effectiveness of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes: A randomised controlled trial","volume":"21","author":"W Jeffcoate","year":"2017","journal-title":"Health Technol Assess"},{"issue":"37","key":"pone.0232395.ref035","first-page":"1","article-title":"Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes","volume":"13","author":"W Jeffcoate","year":"2009","journal-title":"Health Technol Assess"},{"issue":"6","key":"pone.0232395.ref036","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/dmrr.2651","article-title":"Outcomes and cost minimisation associated with outpatient parenteral antimicrobial therapy (OPAT) for foot infections in people with diabetes","volume":"31","author":"M Malone","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"pone.0232395.ref037","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1534734607304626","article-title":"The clinical and economic potential of hyperbaric oxygen therapy in the treatment of diabetic ulceration and other conditions","volume":"6","author":"G McMillan","year":"2007","journal-title":"Int J Low Extrem Wounds"},{"issue":"1","key":"pone.0232395.ref038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jval.2017.07.007","article-title":"An economic evaluation of the impact, cost, and medicare policy implications of chronic nonhealing wounds","volume":"21","author":"SR Nussbaum","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"pone.0232395.ref039","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00019053-200018030-00003","article-title":"Costs of deep foot infections in patients with Diabetes Mellitus","volume":"18","author":"G Ragnarson Tennvall","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"pone.0232395.ref040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1262-3636(07)70154-4","article-title":"Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments","volume":"30","author":"WK Redekop","year":"2004","journal-title":"Diabetes Metab"},{"key":"pone.0232395.ref041","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-015-1141-4","article-title":"The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru","volume":"15","author":"M C\u00e1rdenas","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"pone.0232395.ref042","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/iwj.12653","article-title":"A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia","volume":"14","author":"Q Cheng","year":"2017","journal-title":"Int Wound J"},{"issue":"2","key":"pone.0232395.ref043","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1017\/S0266462308080252","article-title":"Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers","volume":"24","author":"AW Chuck","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"12","key":"pone.0232395.ref044","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.ASW.0000323589.27605.71","article-title":"An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers","volume":"21","author":"EJ Dougherty","year":"2008","journal-title":"Adv Skin Wound Care"},{"issue":"2","key":"pone.0232395.ref045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12968\/jowc.2008.17.2.28181","article-title":"An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers","volume":"17","author":"S Flack","year":"2008","journal-title":"J Wound Care"},{"issue":"3","key":"pone.0232395.ref046","doi-asserted-by":"crossref","first-page":"149","DOI":"10.12968\/jowc.2015.24.3.149","article-title":"Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular\/tissue-derived products","volume":"24","author":"AM Gilligan","year":"2015","journal-title":"J Wound Care"},{"issue":"3","key":"pone.0232395.ref047","doi-asserted-by":"crossref","first-page":"136","DOI":"10.12968\/jowc.2018.27.3.136","article-title":"Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK","volume":"27","author":"JF Guest","year":"2018","journal-title":"J Wound Care"},{"issue":"4","key":"pone.0232395.ref048","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1017\/S0266462303000710","article-title":"Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers","volume":"19","author":"S Guo","year":"2004","journal-title":"J Technol Assess Health Care"},{"issue":"12","key":"pone.0232395.ref049","doi-asserted-by":"crossref","first-page":"808","DOI":"10.12968\/jowc.2019.28.12.808","article-title":"Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers","volume":"28","author":"R Lobmann","year":"2019","journal-title":"J Wound Care"},{"issue":"1","key":"pone.0232395.ref050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/clinids\/24.1.57","article-title":"Cost-effectiveness of ampicillin\/sulbactam versus imipenem\/cilastatin in the treatment of limb-threatening foot infections in diabetic patients","volume":"24","author":"PS McKinnon","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0232395.ref051","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2337\/diacare.27.4.901","article-title":"Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis","volume":"27","author":"MM Ortegon","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"pone.0232395.ref052","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1524-4733.2000.36027.x","article-title":"The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data","volume":"3","author":"U Persson","year":"2000","journal-title":"Value Health"},{"issue":"11","key":"pone.0232395.ref053","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s001250100013","article-title":"Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations","volume":"44","author":"G Ragnarson Tennvall","year":"2001","journal-title":"Diabetologia"},{"issue":"16","key":"pone.0232395.ref054","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2165\/00019053-200321160-00003","article-title":"The cost effectiveness of Apligraf treatment of diabetic foot ulcers","volume":"21","author":"WK Redekop","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"pone.0232395.ref055","doi-asserted-by":"crossref","first-page":"1480249","DOI":"10.1080\/2000625X.2018.1480249","article-title":"Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers","volume":"9","author":"M Romero Prada","year":"2018","journal-title":"Diabet Foot Ankle"},{"issue":"946","key":"pone.0232395.ref056","article-title":"Cost-utility analysis of Heberprot-P as an add-on therapy to good wound care for patients in Slovakia with advanced diabetic foot ulcer","volume":"8","author":"T Tesar","year":"2017","journal-title":"Front Pharmacol"},{"issue":"10","key":"pone.0232395.ref057","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ajhp\/64.10.1080","article-title":"Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections","volume":"64","author":"AD Tice","year":"2007","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"pone.0232395.ref058","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7547\/15-004","article-title":"Cost-effectiveness of becaplermin gel on diabetic foot ulcer healing","volume":"106","author":"CR Waycaster","year":"2016","journal-title":"J Am Podiat Med Assn"},{"issue":"4","key":"pone.0232395.ref059","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12612","article-title":"Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting","volume":"10","author":"B Wu","year":"2018","journal-title":"J Diabetes"},{"issue":"1","key":"pone.0232395.ref060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/wrr.12391","article-title":"WHS guidelines update: Diabetic foot ulcer treatment guidelines","volume":"24","author":"LA Lavery","year":"2016","journal-title":"Wound Rep and Reg"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:33:10Z","timestamp":1722817990000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232395"}},"subtitle":[],"editor":[{"given":"Bart","family":"Ferket","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0232395","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]}}}